Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted December 28, 2007
Nothing new, but important
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Member Program Contributor
Although, it really is nothing new, it is important info.  Metformin should be the first step.
Posted December 26, 2007
A welcome reality check
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Member Program Contributor
This article confirms what I have long suspected.  We doctors spend entirely too much valuable time trying to separate clinical truth from marketing messages.  And many (but not all) of us are tired of hearing our patients complain that they are not using their medicines because they cannot...
Posted December 26, 2007
Joint collaboration between Galapagos NV and Eli Lilly and Company (NYSE:LLY)- Is this going to work ?
Analysis of: Galapagos announces osteoporosis collaboration with Lilly | www.pipelinereview.com
Author: GLG Member Program Contributor
The collaboration between Galapagos NV (Euronext & LSE: GLPG) and Eli Lilly and Company (NYSE:LLY) is expected to show significant progress to develop bone formation for the treatment of osteoporosis at a global level. The news published in the www.pipeline.review shows the complimentary functions...
Posted December 17, 2007
Another nail in its coffin
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Avandia needs definitive studies of its safety to ressurect itself. This study leads to a further reason for no longer using it. People may disagree, but those of us on the front lines are hard pressed using a drug with so much liability baggage.
Posted December 17, 2007
More Glucose Sensor Progress
Analysis of: Dexcom says gets FDA OK to calibrate glucose monitoring system | www.reuters.com
Author: GLG Member Program Contributor
Dexcom is really the leader of the pack of the glucose sensors, in a variety of ways.  For such a small company to be in the lead, is quite impressive.
Posted December 10, 2007
thiazolidinedione demise will support Januvia use
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
This makes it easier for me to avoid mention or suggestion to my patients to try glitazones. I am having an easier time now with prior approvals of Januvia after only a trial of Metformin and sulfonylureas
Posted December 7, 2007
Risk in using Avandia - increase risk of brittle bone disease
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Using animal models, this article has undoubtedly shown the severe consequences of long-term use of Avadia for patients with type 2 diabetes. This news is adding further to the negative effects of Avadia found in previous evidence that the usuage of Avandia is linked to heart disease. The article has...
Posted December 7, 2007
the truth about avandia and osteoporosis
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
-the relationship between avandia and ostoeporosis -implcations in clinical practice -implications for the future of avandia
Jeff Stier Posted December 4, 2007
New Avandia Study Will Do Little To Tip The Scale Against GSK Drug
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: Jeff Stier, Associate Director American Council on Science and Health
GlaxoSmithKline's Avandia is already under scrutiny, but the latest study will do little to tip the scale in terms of the risk/benefit analysis required before taking any medication.
Posted December 3, 2007
Conformation of previous concerns
Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: GLG Member Program Contributor
This drug did not come to market originally because of these concerns. This study only confirms that reasoning for not approving this agent.
Previous Page : 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next111 to 120 of 373

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353